# Meibography: an overview

**Dr Marian Elder** and **Assistant Professor Sruthi Srinivasan** explain the use and significance of the technique of meibography

> he meibomian glands (MGs) play an important role in the maintenance of a healthy ocular surface by providing lipids to the superficial tear film.<sup>1</sup> The MGs are found in the upper and lower eyelids between the palpebral conjunctiva and the tarsal plate. Each MG is approximately 3-4mm in length, ending at the lid margin.<sup>2</sup> The MG functions as a holocrine gland with a tubular, ductal framework and clusters of acini associated that direct lipids towards the gland orifice at the lid margin.<sup>3</sup> These clear lipid secretions, called meibum, form an integral part of a healthy, functional tear film by providing the superficial surface layer, which overlies a thicker muco-aqueous gel and a base mucin layer.4-6 Lack of continuous meibum flow and dilation of the ductal system of the MGs over time results in atrophy of the glands.7 Without adequate lipid production, the tear film is susceptible to evaporation, which eventually leads to ocular surface disease.1

> In 2011, the International Workshop on Meibomian Gland Dysfunction defined meibomian gland dysfunction (MGD) as 'a chronic, diffuse abnormality of the meibomian glands, commonly characterised by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion.<sup>8</sup> This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease.'8 The prevalence of MGD varies widely in the literature from 3.5% to 69.3%, 9-13 likely owing to the fact that the diagnostic criteria for MGD varies between studies but MGD is still thought to be the number one cause of dry eye in clinic and populationbased studies.<sup>12,14-16</sup> Studies in the past have had to rely upon evaluation of the lid margins, MG orifices or meibum quality, which is only the tip of the iceberg with reference to MGs. The ability to image and examine the structure of the acini and ducts that make up the MG provides a more comprehensive view of the

glands themselves and better understanding of the disease process in MG dysfunction.

## METHODS OF ASSESSING MGD

Dry eye disease can be generally categorized as aqueous-deficient dry eye (ADDE) or evaporative dry eye (EDE)<sup>1</sup> but they often overlap.<sup>17</sup> EDE is most commonly associated with MGD.<sup>118</sup> There are various methods to assess MG function including slit lamp biomicroscopy assessment of the lid margins, tear break-up time, expression of the MGs.<sup>19</sup>

MG expression is a useful technique in the evaluation of MGD as it allows the practitioner to evaluate both the ease of gland expression and the quality of the expressed meibum. Pressure is applied to the posterior side of the lid using a specialised paddle or a cotton swab and from the anterior side of the lid or the practitioner's finger. Unfortunately, these observations are purely qualitative and the technique can vary depending on the amount of pressure applied. Devices such as the Korb Meibomian Gland Evaluator (Johnson & Johnson Vision, Jacksonville, FL, USA) allow for more consistent application of pressure when grading MG expression for the purpose of diagnosis or monitoring treatment efficacy. If the goal of gland expression is therapeutic rather than diagnostic, the use of a paddle may be more appropriate. MG expression is a very useful technique both for evaluating and treating MGD.

The meibum expressed by the MGs forms the lipid layer, the outermost layer of the tear film. Evaluating the lipid layer of the tear film gives insight into the overall stability of the tear film but also, indirectly, the function of the MGs. The lipid layer is best evaluated using interferometry techniques, in which light is projected on the tear film to create interference fringe patterns that will vary in colour and pattern according to lipid layer thickness and stability.<sup>20,21</sup> The Tearscope (Keeler) is a handheld device that




FIGURE 1 Everted upper lid when viewed with white light (left) and with IR light on Oculus Keratograph 5M (right)

can be used to assess lipid layer thickness but it is no longer manufactured. The LipiView II (Johnson & Johnson Vision), Keratograph 5M and the EasyTearView+ (Easytear s.r.l.) are other instruments that are capable of tear film interferometry.<sup>22</sup>

Meibometry is a technique that looks at the meibum levels at the eyelid margin by placing meibum samples on a unique tape and photometrically measuring the change in tape transparency.<sup>23</sup> This technique is very susceptible to sampling error as the meibum distribution along the lid margin may be focal or diffuse.<sup>23</sup> It is more of a research-based tool and would not be feasible in a clinical setting.

The evaluation of changes to the morphology of the acini in the MGs is crucial for the diagnosis and management of MGD. Meibography is a technique that allows the full MG structure to be imaged in vivo in a relatively non-invasive manner. Other techniques that allow for evaluation of the gland structure either require biopsy of the posterior lid or confocal microscopy, which may not be feasible outside of a research setting.<sup>24</sup>

#### **MEIBOGRAPHY**

The premise of meibography was first found in the literature in 1977, when Tapie demonstrated using a transilluminator under an everted eye lid and either white light or a UV Woods light to evaluate the MGs.<sup>25</sup> This technique was then used with infrared (IR) photography to further improve image quality in the early 1980s<sup>2</sup> but it was not until 1991 that the term meibography was used to describe using this technique *in vivo* to evaluate the MGs.<sup>26</sup> This method of meibography was further termed contact meibography, as it required the transilluminator to touch the patient's lid.

This basic method was used without major change until 2007.<sup>27</sup> The transilluminator behind the everted eyelid posed many issues related to patient discomfort and overheating of the probe.

The practitioner's experience performing the technique also impacted the image quality and patient comfort. In 2007, a T-shaped probe was proposed for under the everted lid to improve both the ease of image capture and patient comfort,<sup>27</sup> which was promising until the introduction of non-contact meibography the following year. In 2008, Arita et al developed the concept of noncontact meibography which eliminated many of the shortcomings associated with the original technique. Noncontact meibography uses IR light (700-1000mm) projected onto the everted eyelid and an IR-sensitive camera to record the image, removing the need for transillumination of the lid.<sup>28</sup> Because the MGs are IR hyper-reflective, their visibility is enhanced.<sup>29</sup> With this technique, the MG structure will appear light, with dark areas in between the glands versus contact meibography in which the MGs appear dark, with lighter areas in between glands due to transillumination. It is not yet known what part of the MGs provide IR hyper-reflectivity, but this holds potential for future research and technique development.<sup>29</sup>

#### **OTHER METHODS TO IMAGE MG STRUCTURE**

The histopathology of MGs can also be analysed using *in vivo* confocal microscopy.<sup>30-32</sup> This method involves anaesthetising the front surface of the eye and applanating the sterile probe of the laser scanning confocal microscope to the palpebral conjunctiva of the everted lid.<sup>31</sup> The field of view for confocal microscopy is 400x400µm, a significantly smaller area than most non-contact IR meibography.<sup>33,34</sup> While confocal microscopy is not as clinically accessible as other technologies, it does have the ability to diagnose MGD with high sensitivity and specificity.<sup>35</sup> Confocal microscopy provides MG imaging on a cellular level, which would otherwise only be possible via tissue biopsy.

Optical coherence tomography (OCT) is another emerging tool to image the MGs.<sup>36-39</sup> The lid is everted and OCT scans



FIGURE 2 Lower lid when viewed with white light (left) and with IR light on Oculus Keratograph 5M (right)

are captured from various points on the lid<sup>39,40</sup> using a specialised OCT. The field of view of OCT meibography is 4.3x4.3mm, larger than confocal microscopy but still smaller than traditional non-contact IR meibography.<sup>33</sup> OCT meibography allows for volumetric analysis of the MGs and images from the deeper layers of MGs, something that is not possible using IR meibography.<sup>19,33</sup> As more studies emerge examining the use of OCT meibography, this may become a feature found standard on future OCT models.

#### **MEIBOGRAPHY DEVICES**

While the simplest method for performing meibography is contact meibography using a transilluminator and a slit lamp, it is not easy for the patient or the practitioner to perform.<sup>28</sup> There are several devices on the market now that perform non-contact meibography, many adding this feature to a list of other capabilities.

The EasyTearView Plus (Trento, Italy) is a handheld or slitlamp mounted tearscope that is capable of meibography using its built-in IR light and an optional IR camera attachment. TOPCON has the BG-4M slit-lamp biomicroscope which has IR light and an IR camera attached. The COBRA HD fundus camera (CSO, Florence, Italy) has the ability to perform meibography in addition to its other functions as a fundus camera. The LipiScan (Johnson & Johnson Vision, Jacksonville, FL, USA) is a standalone instrument to perform meibography quickly, while the Lipiview 2 (Johnson & Johnson Vision, Jacksonville, FL, USA) device provides meibography among a suite of other capabilities. Many topographers have meibography among their suite of anterior segment imaging capabilities, including the Oculus Keratograph 5M (Oculus, Wetzlar, Germany), the EyeTop corneal topographer (bon, Optic Vertribsges, Lubeck, Germany) and the Sirius Scheimpflug Camera (bon, Optic Vertribsges, Lubeck, Germany). Depending on the overall needs of a clinic or research centre, there are many instruments that offer non-contact meibography, often bundled with other capabilities.

#### **Meibography Grading Methods**

Several methods have been used to grade meibomian gland atrophy including counting glands, estimating areas of gland loss or gland drop-out. Most meibography grading systems use the area of gland loss in order to assign a grade.  $^{28,41,42}$ 

Arita *et al* described the 'meiboscore' in 2008, assigning a grade from 0-3 based on the percentage of the lid area with MG loss or destruction; grade 0 represents no loss of MGs; grade 1 represents gland loss occupying less than 1/3 the total area of MGs; grade 2 represents gland loss between 1/3 to 2/3 the total area; grade 3 represents gland loss greater than 2/3 of the total area of MGs.<sup>28</sup> This is done for the upper and lower lids and summed to give a score from 0-6 for each eye. The 'meiboscale', described by Pult, expanded to a five-grade scale and added meibography images and drawings to further aid in the grading process (figure 3). The lower and upper lids are each assigned a grade from 0-4, with higher grades indicating higher percentages of lid area with gland loss.<sup>43</sup>

The 'meibograde' method is more detailed in that it accounts for gland distortion, gland shortening and gland dropout.<sup>19</sup> Each of these characteristics is graded from 0-3, similar to the meiboscore, and then they are summed to give a total score of 0-9 per eyelid.<sup>44</sup> In all methods of grading MG loss, a higher score represents a higher percentage of gland loss.

Analysing the area of gland loss can also be done objectively using computerised image analysis software like ImageJ.<sup>45</sup> Several grading scales have used four grades as described above, but a finer scale such as the five-grade meiboscale may improve subjective grading<sup>43,46</sup> by providing more distinction between levels of gland loss.

Overall, objective computerised image analysis provides the best inter-observer and intra-observer agreement followed by subjective grading, with finer scales (ie Five grade) performing better than broader scales (ie Four grade).<sup>43,46</sup>

Using meibography as an objective measure in the anterior segment examination provides very clinically useful information. Meibography has been used to demonstrate aging as a risk factor for MGD; as age increases, meiboscore becomes higher and MG area decreases.<sup>21</sup> In patients with allergic conjunctivitis, there is greater distortion of the MGs.<sup>47</sup> Higher meiboscores are found in eyes with various conditions such as phlyctenular keratitis, rosacea and chemotherapy patients.<sup>21</sup> By determining how the MG structure is altered in these various conditions, more specifically targeted therapies can be developed and meibography is poised to be a key technology.

->


# CONCLUSION

MGD is a leading cause of dry eye and meibography has become an important tool in both diagnosis and management of MGD. While the technique has been used for 40 years, it is only in the past 10 years that meibography has reached a point of being clinically accessible through the use of non-contact meibography. Ranging from the most basic equipment to stand-alone devices, meibography can be done quickly and easily in both a research and private practice setting. The advent of validated grading systems for meibography images is crucial for research to continue advancing the field of MG imaging. OCT and confocal microscopy can also provide additional information to supplement IR meibography. The MGs cannot be overlooked and meibography provides a ideal tool for viewing these intricate glands. • Dr Marian Elder and Assistant Professor Sruthi Srinivasan are based at the Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo.

### REFERENCES

- Anonymous, The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, 2007. 5(2): p. 75-92.
- **2** Jester JV, *et al*, In vivo biomicroscopy and photography of meibomian glands in a rabbit model of meibomian gland dysfunction. *Invest Ophthalmol Vis Sci*, 1982. 22(5): p. 660-7.
- **3** Sirigu P, RL Shen, and P Pinto da Silva, Human meibomian glands: the ultrastructure of acinar cells as viewed by thin sec-





tion and freeze-fracture transmission electron microscopies. *Invest Ophthalmol Vis Sci*, 1992. 33(7): p. 2284-92.

- **4** Tiffany, JM. The normal tear film. *Dev Ophthalmol*, 2008. 41: p. 1-20.
- 5 Chen HB, et al. Structure and composition of rat precorneal tear film. A study by an in vivo cryofixation. *Invest Ophthalmol Vis Sci*, 1997. 38(2): p. 381-7.
- 6 Prydal JI and FW Campbell, Study of precorneal tear film

thickness and structure by interferometry and confocal microscopy. *Invest Ophthalmol Vis Sci*, 1992. 33(6): p. 1996-2005.

- 7 Knop E, *et al.* Meibomian glands : part III. Dysfunction argument for a discrete disease entity and as an important cause of dry eye. *Ophthalmologe*, 2009. 106(11): p. 966-79.
- 8 Nelson JD, *et al.* The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. *Invest Ophthalmol Vis Sci*, 2011. 52(4): p. 1930-7.
- **9** Jie Y, *et al*. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. *Eye* (Lond), 2009. 23(3): p. 688-93.
- **10** Schein OD, *et al*. Prevalence of dry eye among the elderly. *Am J Ophthalmol*, 1997. 124(6): p. 723-8.
- **11** Siak JJ, *et al.* Prevalence and risk factors of meibomian gland dysfunction: the Singapore Malay eye study. *Cornea*, 2012. 31(11): p. 1223-8.
- **12** Viso E, *et al.* Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. *Invest Ophthalmol Vis Sci*, 2012. 53(6): p. 2601-6.
- 13 Schaumberg DA, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci, 2011. 52(4): p. 1994-2005.
- **14** Lemp MA, *et al.* Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea*, 2012. 31(5): p. 472-8.
- 15 Viso E, F Gude, and MT Rodriguez-Ares, The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a population-based study in Spain. *Cornea*, 2011. 30(1): p. 1-6.
- 16 Tong L, et al. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci, 2010. 51(7): p. 3449-54.
- **17** Craig JP, *et al.* TFOS DEWS II Definition and Classification Report. *Ocul Surf*, 2017. 15(3): p. 276-283.
- 18 Wolffsohn JS, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf, 2017. 15(3): p. 539-574.
- 19 Wise RJ, RK Sobel, and RC Allen, Meibography: A review of techniques and technologies. *Saudi J Ophthalmol*, 2012. 26(4): p. 349-56.
- 20 Guillon JP, Non-invasive Tearscope Plus routine for contact lens fitting. Cont Lens Anterior Eye, 1998. 21 Suppl 1: p. S31-40.
- **21** Arita R, S Fukuoka, and N Morishige, New insights into the morphology and function of meibomian glands. *Exp Eye Res*, 2017. 163: p. 64-71.
- **22** Elder M, Srinivasan S, Jones L. A new look at tears. *Optician*, 2017: p. 34-36.
- 23 Yokoi N, *et al.* Assessment of meibomian gland function in dry eye using meibometry. *Arch Ophthalmol*, 1999. 117(6): p. 723-9.
- **24** Lee SH and SC Tseng, Rose bengal staining and cytologic characteristics associated with lipid tear deficiency. *Am J Ophthalmol*, 1997. 124(6): p. 736-50.
- **25** Tapie R. Biomicroscopic study of the glands of meibomius]. *Ann Ocul*, 1977. 210: p. 637-48.
- 26 Mathers WD, et al. Meibomian gland dysfunction in chronic blepharitis. Cornea, 1991. 10(4): p. 277-85.
- **27** Yokoi N, *et al*. A newly developed video-meibography system featuring a newly designed probe. *Jpn J Ophthalmol*, 2007. 51(1): p. 53-6.

- **28** Arita R, *et al.* Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. *Ophthalmology*, 2008. 115(5): p. 911-5.
- **29** Pult H and JJ Nichols, A review of meibography. *Optom Vis Sci*, 2012. 89(5): p. E760-9.
- **30** Matsumoto Y, *et al.* The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy. *Graefes Arch Clin Exp Ophthalmol*, 2009. 247(6): p. 821-9.
- **31** Villani E, *et al.* In vivo confocal microscopy of meibomian glands in Sjogren's syndrome. *Invest Ophthalmol Vis Sci*, 2011. 52(2): p. 933-9.
- **32** Villani E, F Mantelli, and P Nucci, In-vivo confocal microscopy of the ocular surface: ocular allergy and dry eye. *Curr Opin Allergy Clin Immunol*, 2013. 13(5): p. 569-76.
- **33** Yoo YS, *et al*. Morphological evaluation for diagnosis of dry eye related to meibomian gland dysfunction. *Exp Eye Res*, 2017. 163: p. 72-77.
- **34** Matsumoto Y, *et al*. The application of in vivo laser confocal microscopy to the diagnosis and evaluation of meibomian gland dysfunction. *Mol Vis*, 2008. 14: p. 1263-71.
- **35** Ibrahim OM, *et al.* The efficacy, sensitivity, and specificity of in vivo laser confocal microscopy in the diagnosis of meibomian gland dysfunction. *Ophthalmology*, 2010. 117(4): p. 665-72.
- **36** Bizheva K, *et al.* In vivo volumetric imaging of the human upper eyelid with ultrahigh-resolution optical coherence tomography. *J Biomed Opt*, 2010. 15(4): p. 040508.
- 37 Napoli PE, et al. A Simple Novel Technique of Infrared Meibography by Means of Spectral-Domain Optical Coherence Tomography: A Cross-Sectional Clinical Study. PLoS One, 2016. 11(10): p. e0165558.
- **38** Yoo YS, *et al.* Examination of Gland Dropout Detected on Infrared Meibography by Using Optical Coherence Tomography Meibography. *Ocul Surf*, 2017. 15(1): p. 130-138 e1.
- **39** Hwang HS, *et al*. In Vivo 3D Meibography of the Human Eyelid Using Real Time Imaging Fourier-Domain OCT. *PLoS One*, 2013. 8(6): p. e67143.
- **40** Liang Q, *et al*. Evaluation of Optical Coherence Tomography Meibography in Patients With Obstructive Meibomian Gland Dysfunction. *Cornea*, 2015. 34(10): p. 1193-9.
- **41** Pflugfelder SC, *et al.* Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. *Cornea*, 1998. 17(1): p. 38-56.
- **42** Nichols JJ, *et al*. An assessment of grading scales for meibography images. *Cornea*, 2005. 24(4): p. 382-8.
- **43** Pult H and B Riede-Pult, Comparison of subjective grading and objective assessment in meibography. *Cont Lens Anterior Eye*, 2013. 36(1): p. 22-7.
- **44** Call CB, *et al.* In vivo examination of meibomian gland morphology in patients with facial nerve palsy using infrared meibography. *Ophthal Plast Reconstr Surg*, 2012. 28(6): p. 396-400.
- **45** Pult H, BH Riede-Pult, and JJ Nichols, Relation between upper and lower lids' meibomian gland morphology, tear film, and dry eye. *Optom Vis Sci*, 2012. 89(3): p. E310-5.
- **46** Ngo W, *et al.* Repeatability of grading meibomian gland dropout using two infrared systems. *Optom Vis Sci*, 2014. 91(6): p. 658-67.
- **47** Arita R, *et al.* Proposed diagnostic criteria for seborrheic meibomian gland dysfunction. *Cornea*, 2010. 29(9): p. 980-4.